A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8(+) T-cell Responses, Impacting Tumor Challenge
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics
